<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN">
<html>
<head>
<title>6 cardiovascular - Phosphodiesterase inhibitors </title>
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<link href="../sgStyles2.css" rel="stylesheet" type="text/css">
</head>

<body>
	<a id="top"></a>
		<div id="text">



<p class="titleSG">Phosphodiesterase inhibitors</p>

<input type="Button" value="Previous Page" onClick="history.go(-1)">

<p>This group of drugs includes such familiar substances as <strong>caffeine</strong> 
  (coffee), <strong>theophylline</strong> (tea) and <strong>theobromine</strong> 
  (chocolate). Most of the drugs used in veterinary practice are esters of theophylline, 
  such as <strong>aminophylline</strong> or <strong>etamiphylline</strong>. Newer 
  PDIs specific for cardiac phosphodiesterase have been produced for human use, 
  these include <strong>amrinone</strong>, <strong>milrinone</strong> and <strong>enoximone</strong>. 
  &#8220;Viagra&#8221; (<strong>sildenafil</strong>) started out as one of these 
  until its interesting side effects were noted. <strong>Oxpentifylline</strong> 
  (pentoxyfylline USAN) is a theophylline type drug which is rather more specific 
  for PDE 4 and has a number of different effects such as TNF&#945; antagonism. It 
  could be useful in CHF but is not usually used.</p>
<p class="footerSG">Mechanism of Action</p>
<p>(<a href="cardInoDia.html">inotropes diagram</a>) Phosphodiesterase normally 
  inactivates cAMP. Inhibition of cAMP degradation leads to increases in intracellular 
  cAMP concentration, and consequent increases in activity of cAMP-dependent protein 
  kinase. This activates many intracellular enzymes by phosphorylation. Calcium 
  dependent enzymes are also activated, leading to stimulation of contractility 
  due to increased effects of intracellular calcium. Their effects are additive 
  with digoxin.<br>
  These drugs increase the rate and force of myocardial contraction. They also 
  cause some bronchial and systemic arterial dilatation and increase the alertness 
  of the animal, all of which is useful in dogs with CHF. There are at least 11 
  different types of phosphodiesterase (and numerous subtypes), so the range of 
  effects is large.</p>
<p>
<TABLE border="1" cellspacing="0" bordercolor="#000000" width="700" height="186">
  <TR> 
    <TD bgcolor="#ff6666" width="56" height="15" valign="top" style="padding-left: 1;border-bottom: 0pt padding-right: 1;border-right: 0pt padding-top: 0;border-top: 0pt padding-bottom: 0;border-bottom: 0pt "> 
       <strong>enzyme<BR>
        </SPAN> </strong></DIV></TD>
    <TD bgcolor="#ff6666" width="100" height="15" valign="top" style="padding-left: 1;border-bottom: 0pt padding-right: 1;border-right: 0pt padding-top: 0;border-top: 0pt padding-bottom: 0;border-bottom: 0pt "> 
       <strong>subtypes<BR>
        </SPAN> </strong></DIV></TD>
    <TD bgcolor="#ff6666" width="300" height="15" valign="top" style="padding-left: 1;border-bottom: 0pt padding-right: 1;border-right: 0pt padding-top: 0;border-top: 0pt padding-bottom: 0;border-bottom: 0pt "> 
       <strong>tissue<BR>
        </SPAN> </strong></DIV></TD>
    <TD bgcolor="#ff6666" width="200" height="15" valign="top" style="padding-left: 1;border-bottom: 0pt padding-right: 1;border-right: 0pt padding-top: 0;border-top: 0pt padding-bottom: 0;border-bottom: 0pt "> 
       <strong>inhibitors<BR>
        </SPAN> </strong></DIV></TD>
  </TR>
  <TR> 
    <TD width="56" height="15" valign="top" style="padding-left: 1;border-bottom: 0pt padding-right: 1;border-right: 0pt padding-top: 0;border-top: 0pt padding-bottom: 0;border-bottom: 0pt "> 
       PDE1<BR>
        </SPAN> </DIV></TD>
    <TD width="100" height="15" valign="top" style="padding-left: 1;border-bottom: 0pt padding-right: 1;border-right: 0pt padding-top: 0;border-top: 0pt padding-bottom: 0;border-bottom: 0pt "> 
       A, B, C<BR>
        </SPAN> </DIV></TD>
    <TD width="300" height="15" valign="top" style="padding-left: 1;border-bottom: 0pt padding-right: 1;border-right: 0pt padding-top: 0;border-top: 0pt padding-bottom: 0;border-bottom: 0pt "> 
       CNS, blood 
        vessels<BR>
        </SPAN> </DIV></TD>
    <TD width="200" height="15" valign="top" style="padding-left: 1;border-bottom: 0pt padding-right: 1;border-right: 0pt padding-top: 0;border-top: 0pt padding-bottom: 0;border-bottom: 0pt "> 
       <BR>
        </SPAN> </DIV></TD>
  </TR>
  <TR> 
    <TD width="56" height="15" valign="top" style="padding-left: 1;border-bottom: 0pt padding-right: 1;border-right: 0pt padding-top: 0;border-top: 0pt padding-bottom: 0;border-bottom: 0pt "> 
       PDE2<BR>
        </SPAN> </DIV></TD>
    <TD width="100" height="15" valign="top" style="padding-left: 1;border-bottom: 0pt padding-right: 1;border-right: 0pt padding-top: 0;border-top: 0pt padding-bottom: 0;border-bottom: 0pt "> 
       A<BR>
        </SPAN> </DIV></TD>
    <TD width="300" height="15" valign="top" style="padding-left: 1;border-bottom: 0pt padding-right: 1;border-right: 0pt padding-top: 0;border-top: 0pt padding-bottom: 0;border-bottom: 0pt "> 
       <BR>
        </SPAN> </DIV></TD>
    <TD width="200" height="15" valign="top" style="padding-left: 1;border-bottom: 0pt padding-right: 1;border-right: 0pt padding-top: 0;border-top: 0pt padding-bottom: 0;border-bottom: 0pt "> 
       <BR>
        </SPAN> </DIV></TD>
  </TR>
  <TR> 
    <TD width="56" height="15" valign="top" style="padding-left: 1;border-bottom: 0pt padding-right: 1;border-right: 0pt padding-top: 0;border-top: 0pt padding-bottom: 0;border-bottom: 0pt "> 
       PDE3<BR>
        </SPAN> </DIV></TD>
    <TD width="100" height="15" valign="top" style="padding-left: 1;border-bottom: 0pt padding-right: 1;border-right: 0pt padding-top: 0;border-top: 0pt padding-bottom: 0;border-bottom: 0pt "> 
       A, B<BR>
        </SPAN> </DIV></TD>
    <TD width="300" height="15" valign="top" style="padding-left: 1;border-bottom: 0pt padding-right: 1;border-right: 0pt padding-top: 0;border-top: 0pt padding-bottom: 0;border-bottom: 0pt "> 
      myocardium, blood vessels<BR>
        </SPAN> </DIV></TD>
    <TD width="200" height="15" valign="top" style="padding-left: 1;border-bottom: 0pt padding-right: 1;border-right: 0pt padding-top: 0;border-top: 0pt padding-bottom: 0;border-bottom: 0pt "> 
       milrinone, 
        pimobendan, <BR>
        </SPAN> </DIV></TD>
  </TR>
  <TR> 
    <TD width="56" height="15" valign="top" style="padding-left: 1;border-bottom: 0pt padding-right: 1;border-right: 0pt padding-top: 0;border-top: 0pt padding-bottom: 0;border-bottom: 0pt "> 
       PDE4<BR>
        </SPAN> </DIV></TD>
    <TD width="100" height="15" valign="top" style="padding-left: 1;border-bottom: 0pt padding-right: 1;border-right: 0pt padding-top: 0;border-top: 0pt padding-bottom: 0;border-bottom: 0pt "> 
       A, B, C, 
        D<BR>
        </SPAN> </DIV></TD>
    <TD width="300" height="15" valign="top" style="padding-left: 1;border-bottom: 0pt padding-right: 1;border-right: 0pt padding-top: 0;border-top: 0pt padding-bottom: 0;border-bottom: 0pt "> 
       airways, 
        inflammatory cells, CNS, stomach<BR>
        </SPAN> </DIV></TD>
    <TD width="200" height="15" valign="top" style="padding-left: 1;border-bottom: 0pt padding-right: 1;border-right: 0pt padding-top: 0;border-top: 0pt padding-bottom: 0;border-bottom: 0pt "> 
       rolipram, 
        oxpentifylline, <BR>
        </SPAN> </DIV></TD>
  </TR>
  <TR> 
    <TD width="56" height="15" valign="top" style="padding-left: 1;border-bottom: 0pt padding-right: 1;border-right: 0pt padding-top: 0;border-top: 0pt padding-bottom: 0;border-bottom: 0pt "> 
       PDE5<BR>
        </SPAN> </DIV></TD>
    <TD width="100" height="15" valign="top" style="padding-left: 1;border-bottom: 0pt padding-right: 1;border-right: 0pt padding-top: 0;border-top: 0pt padding-bottom: 0;border-bottom: 0pt "> 
       A<BR>
        </SPAN> </DIV></TD>
    <TD width="300" height="15" valign="top" style="padding-left: 1;border-bottom: 0pt padding-right: 1;border-right: 0pt padding-top: 0;border-top: 0pt padding-bottom: 0;border-bottom: 0pt "> 
       blood vessels, 
        platelets<BR>
        </SPAN> </DIV></TD>
    <TD width="200" height="15" valign="top" style="padding-left: 1;border-bottom: 0pt padding-right: 1;border-right: 0pt padding-top: 0;border-top: 0pt padding-bottom: 0;border-bottom: 0pt "> 
       sildenafil, 
        <BR>
        </SPAN> </DIV></TD>
  </TR>
  <TR> 
    <TD width="56" height="15" valign="top" style="padding-left: 1;border-bottom: 0pt padding-right: 1;border-right: 0pt padding-top: 0;border-top: 0pt padding-bottom: 0;border-bottom: 0pt "> 
       PDE6<BR>
        </SPAN> </DIV></TD>
    <TD width="100" height="15" valign="top" style="padding-left: 1;border-bottom: 0pt padding-right: 1;border-right: 0pt padding-top: 0;border-top: 0pt padding-bottom: 0;border-bottom: 0pt "> 
       A, B, C, 
        D, G, H<BR>
        </SPAN> </DIV></TD>
    <TD width="300" height="15" valign="top" style="padding-left: 1;border-bottom: 0pt padding-right: 1;border-right: 0pt padding-top: 0;border-top: 0pt padding-bottom: 0;border-bottom: 0pt "> 
       retina<BR>
        </SPAN> </DIV></TD>
    <TD width="200" height="15" valign="top" style="padding-left: 1;border-bottom: 0pt padding-right: 1;border-right: 0pt padding-top: 0;border-top: 0pt padding-bottom: 0;border-bottom: 0pt "> 
       sildenafil,<BR>
        </SPAN> </DIV></TD>
  </TR>
  <TR> 
    <TD width="56" height="15" valign="top" style="padding-left: 1;border-bottom: 0pt padding-right: 1;border-right: 0pt padding-top: 0;border-top: 0pt padding-bottom: 0;border-bottom: 0pt "> 
       PDE7<BR>
        </SPAN> </DIV></TD>
    <TD width="100" height="15" valign="top" style="padding-left: 1;border-bottom: 0pt padding-right: 1;border-right: 0pt padding-top: 0;border-top: 0pt padding-bottom: 0;border-bottom: 0pt "> 
       A, B<BR>
        </SPAN> </DIV></TD>
    <TD width="300" height="15" valign="top" style="padding-left: 1;border-bottom: 0pt padding-right: 1;border-right: 0pt padding-top: 0;border-top: 0pt padding-bottom: 0;border-bottom: 0pt "> 
       skeletal 
        muscle<BR>
        </SPAN> </DIV></TD>
    <TD width="200" height="15" valign="top" style="padding-left: 1;border-bottom: 0pt padding-right: 1;border-right: 0pt padding-top: 0;border-top: 0pt padding-bottom: 0;border-bottom: 0pt "> 
       <BR>
        </SPAN> </DIV></TD>
  </TR>
  <TR> 
    <TD width="56" height="15" valign="top" style="padding-left: 1;border-bottom: 0pt padding-right: 1;border-right: 0pt padding-top: 0;border-top: 0pt padding-bottom: 0;border-bottom: 0pt "> 
       PDE8<BR>
        </SPAN> </DIV></TD>
    <TD width="100" height="15" valign="top" style="padding-left: 1;border-bottom: 0pt padding-right: 1;border-right: 0pt padding-top: 0;border-top: 0pt padding-bottom: 0;border-bottom: 0pt "> 
       A, B<BR>
        </SPAN> </DIV></TD>
    <TD width="300" height="15" valign="top" style="padding-left: 1;border-bottom: 0pt padding-right: 1;border-right: 0pt padding-top: 0;border-top: 0pt padding-bottom: 0;border-bottom: 0pt "> 
       <BR>
        </SPAN> </DIV></TD>
    <TD width="200" height="15" valign="top" style="padding-left: 1;border-bottom: 0pt padding-right: 1;border-right: 0pt padding-top: 0;border-top: 0pt padding-bottom: 0;border-bottom: 0pt "> 
       <BR>
        </SPAN> </DIV></TD>
  </TR>
  <TR> 
    <TD width="56" height="15" valign="top" style="padding-left: 1;border-bottom: 0pt padding-right: 1;border-right: 0pt padding-top: 0;border-top: 0pt padding-bottom: 0;border-bottom: 0pt "> 
       PDE9<BR>
        </SPAN> </DIV></TD>
    <TD width="100" height="15" valign="top" style="padding-left: 1;border-bottom: 0pt padding-right: 1;border-right: 0pt padding-top: 0;border-top: 0pt padding-bottom: 0;border-bottom: 0pt "> 
       A<BR>
        </SPAN> </DIV></TD>
    <TD width="300" height="15" valign="top" style="padding-left: 1;border-bottom: 0pt padding-right: 1;border-right: 0pt padding-top: 0;border-top: 0pt padding-bottom: 0;border-bottom: 0pt "> 
       <BR>
        </SPAN> </DIV></TD>
    <TD width="200" height="15" valign="top" style="padding-left: 1;border-bottom: 0pt padding-right: 1;border-right: 0pt padding-top: 0;border-top: 0pt padding-bottom: 0;border-bottom: 0pt "> 
       <BR>
        </SPAN> </DIV></TD>
  </TR>
  <TR> 
    <TD width="56" height="15" valign="top" style="padding-left: 1;border-bottom: 0pt padding-right: 1;border-right: 0pt padding-top: 0;border-top: 0pt padding-bottom: 0;border-bottom: 0pt "> 
       PDE10<BR>
        </SPAN> </DIV></TD>
    <TD width="100" height="15" valign="top" style="padding-left: 1;border-bottom: 0pt padding-right: 1;border-right: 0pt padding-top: 0;border-top: 0pt padding-bottom: 0;border-bottom: 0pt "> 
       A<BR>
        </SPAN> </DIV></TD>
    <TD width="300" height="15" valign="top" style="padding-left: 1;border-bottom: 0pt padding-right: 1;border-right: 0pt padding-top: 0;border-top: 0pt padding-bottom: 0;border-bottom: 0pt "> 
       <BR>
        </SPAN> </DIV></TD>
    <TD width="200" height="15" valign="top" style="padding-left: 1;border-bottom: 0pt padding-right: 1;border-right: 0pt padding-top: 0;border-top: 0pt padding-bottom: 0;border-bottom: 0pt "> 
       <BR>
        </SPAN> </DIV></TD>
  </TR>
  <TR> 
    <TD width="56" height="15" valign="top" style="padding-left: 1;border-bottom: 0pt padding-right: 1;border-right: 0pt padding-top: 0;border-top: 0pt padding-bottom: 0;border-bottom: 0pt "> 
       PDE11<BR>
        </SPAN> </DIV></TD>
    <TD width="100" height="15" valign="top" style="padding-left: 1;border-bottom: 0pt padding-right: 1;border-right: 0pt padding-top: 0;border-top: 0pt padding-bottom: 0;border-bottom: 0pt "> 
       A<BR>
        </SPAN> </DIV></TD>
    <TD width="300" height="15" valign="top" style="padding-left: 1;border-bottom: 0pt padding-right: 1;border-right: 0pt padding-top: 0;border-top: 0pt padding-bottom: 0;border-bottom: 0pt "> 
       <BR>
        </SPAN> </DIV></TD>
    <TD width="200" height="15" valign="top" style="padding-left: 1;border-bottom: 0pt padding-right: 1;border-right: 0pt padding-top: 0;border-top: 0pt padding-bottom: 0;border-bottom: 0pt "> 
       <BR>
        </SPAN> </DIV></TD>
  </TR>
</TABLE>
<p class="caption">Phosphodiesterase isoenzymes. Theophylline (and papaverine) 
  are non-specific inhibitors.</p>
<p>The cardiac specific phosphodiesterase inhibitors (PDI3s) were initially widely 
  touted as an alternative to digitalis in man but are going out of fashion as 
  although they alleviate congestive heart failure, they reduce survival time 
  in man. They seem to improve the quality of life but increase the chances of 
  sudden death, probably from arrhythmias. This is probably acceptable in animals.<br>
  PDI4s are currently undergoing investigation as anti-inflammatory drugs. Sildenafil 
  is a PDI5.</p>
<p class="footerSG">Drugs</p>
		<p><strong>Methylxanthines</strong> <br>
  Methylxanthines (usually theophylline esters such as <strong>aminophylline</strong> 
  or <strong>etamiphylline</strong>) are also adenosine A2 receptor antagonists. 
  Adenosine is secreted by most cells in response to high energy usage compared 
  to oxygen availability, and acts as an autacoid to decrease the oxygen demand 
  and to increase oxygen availability through alterations to blood flow.<br>
  <em>Effects</em><br>
  Methylxanthines act as weak positive inotropes, but more importantly they relax 
  smooth muscle in bronchi and pulmonary vasculature. They induce diuresis both 
  by increasing cardiac output and hence renal blood flow, and by increasing renal 
  blood flow directly through blockade of adenosine's vasoconstrictive actions 
  in renal vessels. Methylxanthines may also cause central stimulation which is 
  probably a major part of their clinical effect (a previously lethargic dog becomes 
  active again). The relative importance of these effects is different for each 
  drug.<br>
			<em>Side effects</em></p>
		<ul>
			<li>CNS excitation - restlessness to convulsions
			<li>tachycardia which can lead on to ventricular tachyarrhythmias and sudden death
			<li>tachypnoea
		</ul>
		<p><em>Indications</em><br>
			mild congestive heart failure, for bronchodilator effects in patients with myocardial 
  failure, pulmonary oedema or asthma.<br>
			<em>Care</em><br>
			use with caution in animals with</p>
		<ul>
			<li>severe cardiac disease
			<li>gastric ulcers as it induces gastric acid secretion
			<li>hyperthyroidism
			<li>renal or hepatic disease
			<li>antagonises &#946; blocker effects
		</ul>
		<p><em>Dose</em><br>
			Theophyllines have a low therapeutic index so determine dosage correctly. Dose 
  obese animals on their lean body weight. Sustained release products offer the 
  advantage of less frequent dosing, better owner compliance and less fluctuation 
  in blood levels but results may be erratic in animals. im injection is painful; 
  iv injection must be very slow, though because of good bioavailability of oral 
  preparations it is rarely used.</p>
		<p><strong>Other drugs</strong><br>
  <strong>Amrinone</strong> was the first specific cardiac phosphodiesterase inhibitor 
  but is no longer available in NZ. An intravenous bolus of amrinone in dogs leads 
  to a 60 -100% increase in cardiac contractile force which lasts 5 - 20 minutes, 
  and a 10 - 30% increase in systemic arterial blood pressure. In humans amrinone 
  improves left ventricular performance and this effect is sustained. Withdrawal 
  of therapy results in cardiac decompensation. It was used for short term management 
  of congestive heart failure refractory to other treatment. Its long term efficacy 
  for congestive heart disease has not been evaluated in animals, in people long 
  term survival is reduced.</p>
<p><strong>Milrinone</strong> is the only cardiac specific PDI available here. 
  It is a methylcarbonitrile derivative of amrinone which is 20 to 30 times more 
  potent than amrinone. Its cardiovascular effects are reported to be similar 
  to those of amrinone but without increases in heart rate. In one trial approxiamately 
  70% of dogs with myocardial failure responded well to this drug.<br>
  Its short half life and duaration of action in dogs mean that it usually has 
  to be given four times daily so is not really practical for outpatients.<br>
  Milrinone has a large therapeutic ratio. Ventricular arrhthymias occur in &lt; 
  5% of dogs with myocardial failure.</p>
<p><strong>Pimobendan</strong> is a similar drug which has recently been licensed 
  for use in dogs. In addition to PD inhibition, it is also supposed to &quot;sensitise&quot; 
  the myocardium to calcium. This effect is likely to be useful since it involves 
  no extra oxygen consumption and the myocardial calcium modulation is impaired 
  in CHF. It prolongs life in dogs in dilated cardiomyopathy but not in valvular 
  insufficiency. It is usually used in combination with ACE inhibitors and frusemide. 
  Like the methylxanthines, its major effect in many dogs may be in the CNS to 
  make the dog feel better.</p>
<p><strong>Oxpentifylline</strong> (pentoxyfylline USAN) is not normally used 
  to treat CHF, but may be useful, both as a PDE inhibitor and as a tumour necrosis 
  factor &#945; antagonist (reduces myocardial inflammation).</p>
		<p><a href="../../lectureSite/PharmLec4/04dig&PDEi.pdf">Digitalis and PDIs lecture</a></p>
		<table width="90%" border="0" align="center">
  <tr> 
    <td class="titleSG"><a href="cardIndex.html" class="aTitle">6 Cardiovascular 
      index</a></td>
    <td width="50%" class="titleSG">
<div align="right"><a href="cardHFindex.html" class="aTitle">Heart failure index</a></div></td>
  </tr>
</table>
<br>
<table width="90%" border="0" align="center">
  <tr align="center">
    <td>    <a href="../../indexpharm.html"><img src="../../PharmBut.gif" width="100" height="21" border="0"></a></td>
    <td><a href="../../toxSite/indexTox.html"><img src="../../ToxBut.gif" width="100" height="21" border="0"></a></td>
    <td><a href="../indexSG.html"><img src="../../SGbut.gif" width="100" height="21" border="0"></a></td>
    <td><a href="../../lectureSite/indexLec.html"><img src="../../LecBut.gif" width="100" height="21" border="0"></a></td>
    <td><a href="../../formSite/Aform.html" target="_blank"><img src="../../FormBut.gif" width="100" height="21" border="0"></a></td>
    <td><a href="../../casesSite/indexCases.html"><img src="../../CaseBut.gif" width="100" height="21" border="0"></a></td>
  </tr>
</table>
<br>
<table width="90%" border="0" align="center" cellpadding="2" cellspacing="0">
  <tr bgcolor="#FFFFFF">
    <td width="50%" class="commonname"><img src="../../pharmBits/images/mulogo.gif" width="170" height="25"></td>
    <td width="50%" align="right" class="references"><div align="right">copyright
        Massey University</div>
    </td>
  </tr>
</table>
<p>&nbsp;</p>
</div>
</body>
</html>
